Why Cell Therapy Needs a Digital Backbone
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
False
Advertisement
Development & Clinical
What Did ASCO 2026 Reveal About the Future of Oncology?
By James Strachan
August 6, 2026
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
8 min read
How China Is Rewriting the Rules Global Drug Development
By James Strachan
August 5, 2026
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
14 min read
The 10 Biggest Bottlenecks Slowing Drug Development
August 4, 2026
Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back
6 min read
This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
Musings from The Power List: Claudia Zylberberg
July 30, 2026
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
8 min read
The New Rules of Global Drug Development
By James Strachan
July 28, 2026
Caidya Executive Chairman Lingshi Tan explains why capital discipline, early clinical execution, and global development strategy are becoming central to biotech success
8 min read
The Confidentiality Barrier to AI-Enabled Drug Development
By Timothy Pas, Laure Descamps
July 27, 2026
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
3 min read
Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs
July 24, 2026
Industry experts share practical advice for emerging biotech companies navigating development decisions, funding pressures, manufacturing strategy, partner selection, and the path toward commercial readiness
9 min read
Biopharma Vital Signs – Part 5: Capabilities for a Changing Landscape
July 17, 2026
Experts discuss the capabilities companies need to make drug development faster, more flexible, and more resilient – from integrated development and manufacturing flexibility to digital tools, supply chain strategy, and sharper decision-mak...
13 min read
